Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.

@article{Vidal2005ParadoxicalRT,
  title={Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis.},
  author={Carolina Garcia Vidal and Serena Rodr{\'i}guez Fern{\'a}ndez and Javier Mart{\'i}nez Lacasa and Miquel Salavert and Rafael Ara{\'u}jo Vidal and M{\'o}nica Rodr{\'i}guez Carballeira and Javier Garau},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2005},
  volume={40 5},
  pages={756-9}
}
Six of 284 patients treated with infliximab developed active tuberculosis. Four (67%) of these patients had a paradoxical response to antituberculous therapy. Physicians should be aware of the increased risk of a paradoxical response in this population and should consider the use of corticosteroids when a paradoxical reaction is suspected.